Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INVA Stock Forecast 2025-2026
$20.73
Current Price
$1.55B
Market Cap
Buy 3
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to INVA Price Targets
+117.1%
To High Target of $45.00
+59.2%
To Median Target of $33.00
-13.2%
To Low Target of $18.00
INVA Price Momentum
-4.6%
1 Week Change
-0.6%
1 Month Change
+8.8%
1 Year Change
+19.5%
Year-to-Date Change
-8.9%
From 52W High of $22.76
+25.5%
From 52W Low of $16.52
📊 TOP ANALYST CALLS
Did INVA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Innoviva is one of their latest high-conviction picks.
Latest INVA Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, INVA has a bullish consensus with a median price target of $33.00 (ranging from $18.00 to $45.00). The overall analyst rating is N/A (N/A/10). Currently trading at $20.73, the median forecast implies a 59.2% upside. This outlook is supported by 3 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 117.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INVA Analyst Ratings
3
Buy
0
Hold
1
Sell
INVA Price Target Range
Low
$18.00
Average
$33.00
High
$45.00
Current: $20.73
Latest INVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 6, 2025 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Maintains | $31.00 |
| Sep 30, 2025 | Goldman Sachs | Asad Haider | Sell | Initiates | $17.00 |
| Aug 11, 2025 | Oppenheimer | Trevor Allred | Outperform | Initiates | $35.00 |
| Aug 11, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $45.00 |
| Jul 14, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $40.00 |
| Jul 11, 2025 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Initiates | $26.00 |
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Outperform | Initiates | $55.00 |
| Aug 1, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Jul 30, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Jun 18, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Initiates | $N/A |
| May 10, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $22.50 |
| Apr 20, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $22.50 |
| Mar 3, 2023 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $13.00 |
| Mar 3, 2023 | Morgan Stanley | Matthew Harrison | Underweight | Maintains | $10.00 |
| Mar 3, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $22.50 |
| Jan 24, 2023 | Morgan Stanley | Matthew Harrison | Underweight | Maintains | $13.00 |
| Oct 13, 2022 | Morgan Stanley | Matthew Harrison | Underweight | Maintains | $14.00 |
| Aug 8, 2022 | Morgan Stanley | Matthew Harrison | Underweight | Maintains | $13.00 |
| Jul 20, 2022 | Goldman Sachs | Neutral | Initiates | $N/A |
Innoviva Inc. (INVA) Competitors
The following stocks are similar to Innoviva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Innoviva Inc. (INVA) Financial Data
Innoviva Inc. has a market capitalization of $1.55B with a P/E ratio of 12.5x. The company generates $388.52M in trailing twelve-month revenue with a 32.8% profit margin.
Revenue growth is +20.4% quarter-over-quarter, while maintaining an operating margin of +35.3% and return on equity of +15.2%.
Valuation Metrics
Market Cap
$1.55B
Enterprise Value
$1.34B
P/E Ratio
12.5x
PEG Ratio
0.0x
Price/Sales
4.0x
Growth & Margins
Revenue Growth (YoY)
+20.4%
Gross Margin
+70.1%
Operating Margin
+35.3%
Net Margin
+32.8%
EPS Growth
+7,312.0%
Financial Health
Cash/Price Ratio
+34.4%
Current Ratio
14.1x
Debt/Equity
32.0x
ROE
+15.2%
ROA
+8.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Innoviva Inc. (INVA) Business Model
About Innoviva Inc.
What They Do
Pharmaceutical company specializing in royalty management.
Business Model
The company generates revenue by managing royalty portfolios from collaborations with external partners, primarily in the respiratory disease space. Innoviva Inc. focuses on optimizing the value of its intellectual property through strategic partnerships with major pharmaceutical companies, allowing it to maximize returns while minimizing the risks typically associated with drug development.
Additional Information
Founded in 1996 as Theravance, Innoviva Inc. has shifted its focus towards royalty management and investment in biopharmaceutical innovations. Its involvement in co-developing medicines for chronic obstructive pulmonary disease (COPD) and asthma positions it as a significant player in the healthcare sector, particularly in the pharmaceuticals and biotechnology industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
127
CEO
Mr. Pavel Raifeld C.F.A.
Country
United States
IPO Year
2004
Website
www.inva.comInnoviva Inc. (INVA) Latest News & Analysis
Latest News
Quick Summary
Innoviva, Inc. (NASDAQ: INVA) will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025, in New York.
Why It Matters
Innoviva's participation in the Piper Sandler Healthcare Conference highlights its strategic positioning and potential growth in healthcare, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
1 month ago
Quick Summary
Innoviva, Inc. (NASDAQ: INVA) reported strong Q3 2025 financial results and highlighted corporate progress, focusing on its royalties portfolio and healthcare investments.
Why It Matters
Innoviva's strong third-quarter financial results and corporate progress indicate robust performance, potentially boosting investor confidence and impacting stock valuation positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Innoviva (INVA) reported Q3 earnings of $1.08 per share, exceeding the Zacks Consensus Estimate of $0.46. This is a significant increase from $0.02 per share in the same quarter last year.
Why It Matters
Innoviva's strong earnings beat indicates robust financial performance, potentially boosting investor confidence and driving stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Antheia has appointed Eric d'Esparbes as CFO to guide its financial strategy amid continued global expansion and commercialization efforts.
Why It Matters
Eric d'Esparbes' appointment as CFO signals a strategic focus on financial management during Antheia's global expansion, which could enhance operational efficiency and drive shareholder value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Innoviva (INVA) saw a rise in share price with above-average trading volume, but recent earnings estimate revisions indicate potential weakness ahead.
Why It Matters
Innoviva's recent share price surge on high volume signals market interest, but weak earnings revisions indicate potential future challenges, affecting investor sentiment and risk assessment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Innoviva Specialty Therapeutics will present new data on its oral antibiotic zoliflodacin for treating uncomplicated gonorrhea at IDWeek 2025 in Atlanta, GA, from October 19-22, 2025.
Why It Matters
New data on zoliflodacin could impact market perception of Innoviva's growth potential and competitiveness in the antibiotic sector, influencing stock performance leading up to the conference.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About INVA Stock
What is Innoviva Inc.'s (INVA) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Innoviva Inc. (INVA) has a median price target of $33.00. The highest price target is $45.00 and the lowest is $18.00.
Is INVA stock a good investment in 2026?
According to current analyst ratings, INVA has 3 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $20.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INVA stock?
Wall Street analysts predict INVA stock could reach $33.00 in the next 12 months. This represents a 59.2% increase from the current price of $20.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Innoviva Inc.'s business model?
The company generates revenue by managing royalty portfolios from collaborations with external partners, primarily in the respiratory disease space. Innoviva Inc. focuses on optimizing the value of its intellectual property through strategic partnerships with major pharmaceutical companies, allowing it to maximize returns while minimizing the risks typically associated with drug development.
What is the highest forecasted price for INVA Innoviva Inc.?
The highest price target for INVA is $45.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 117.1% increase from the current price of $20.73.
What is the lowest forecasted price for INVA Innoviva Inc.?
The lowest price target for INVA is $18.00 from at , which represents a -13.2% decrease from the current price of $20.73.
What is the overall INVA consensus from analysts for Innoviva Inc.?
The overall analyst consensus for INVA is bullish. Out of 10 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $33.00.
How accurate are INVA stock price projections?
Stock price projections, including those for Innoviva Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:12 PM UTC